Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) EBITDA: 2015-2024

Historic EBITDA for Insight Molecular Diagnostics (IMDX) over the last 10 years, with Dec 2024 value amounting to -$61.0 million.

  • Insight Molecular Diagnostics' EBITDA rose 18.25% to -$11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$61.3 million, marking a year-over-year decrease of 40.66%. This contributed to the annual value of -$61.0 million for FY2024, which is 142.84% down from last year.
  • According to the latest figures from FY2024, Insight Molecular Diagnostics' EBITDA is -$61.0 million, which was down 142.84% from -$25.1 million recorded in FY2023.
  • Insight Molecular Diagnostics' EBITDA's 5-year high stood at -$18.0 million during FY2022, with a 5-year trough of -$61.0 million in FY2024.
  • In the last 3 years, Insight Molecular Diagnostics' EBITDA had a median value of -$25.1 million in 2023 and averaged -$34.7 million.
  • Its EBITDA has fluctuated over the past 5 years, first surged by 66.50% in 2022, then slumped by 142.84% in 2024.
  • Yearly analysis of 5 years shows Insight Molecular Diagnostics' EBITDA stood at -$29.7 million in 2020, then crashed by 80.83% to -$53.7 million in 2021, then surged by 66.50% to -$18.0 million in 2022, then tumbled by 39.67% to -$25.1 million in 2023, then plummeted by 142.84% to -$61.0 million in 2024.